Preparation method and application of psoriasis repair factor preparation
By treating MSCs with intense pulsed light and extracting their exosomes, a psoriasis repair factor preparation was prepared, which solved the problem of poor treatment effect of MSC transplantation and achieved effective regulation and inflammation reduction in psoriasis.
Patent Information
- Application Number
- CN202411030328.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-15
AI Technical Summary
Existing methods for treating psoriasis by directly transplanting mesenchymal stem cells (MSCs) have problems such as poor treatment efficacy and significant inflammatory response.
Mesenchymal stem cells (MSCs) were treated with intense pulsed light, and their exosomes were isolated and extracted to prepare a psoriasis repair factor preparation containing factors such as insulin-like growth factor-1 (IGF-1), interleukin-10 (IL-10), and cytokine signaling inhibitory factor 3 (SOCS-3), which are used to regulate glucose metabolism and immune response of keratinocytes.
By regulating glucose metabolism and immune response in keratinocytes, inhibiting TSLP expression, promoting Treg cell proliferation, reducing inflammation and hyperplasia in psoriasis, and improving psoriasis symptoms.
Smart Images

Figure CN118948895A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of psoriasis treatment preparations, and in particular to a preparation method and application of a psoriasis repair factor preparation. Background Art
[0002] Psoriasis is a common immune-mediated inflammatory disease with a high incidence and a serious impact on the quality of life of patients. As a systemic inflammatory response, patients with the disease are more likely to develop metabolic disorders (insulin resistance, atherosclerotic dyslipidemia, arterial hypertension, and cardiovascular disease) than the general population, which leads to a shortened lifespan, and psoriasis patients are more likely to have suicidal thoughts. Psoriasis poses a serious socioeconomic burden not only to patients but also to the healthcare system. The complex interactions between genetic, epigenetic, immune, and environmental factors in the pathogenesis of the disease are not fully understood. In recent years, the emergence of biological drugs targeting key immune pathways involved in the pathogenesis of psoriasis has provided great support for the treatment of psoriasis. However, these targeted drugs cannot completely cure and have some limitations, such as decreased efficacy over time, severe adverse reactions, and relapse after discontinuation of medication, resulting in an increasing number of psoriasis patients being ineffective for systemic treatment. Therefore, there is an urgent need for breakthroughs in the treatment and non-drug strategies for severe psoriasis.
[0003] Psoriasis is characterized by epidermal hyperplasia and dermal infiltration of immune cells, and its pathogenesis is complex, involving interactions between keratinocytes, immune cells, and other skin-resident cells. Psoriasis has long been considered an immune cell-driven disease, and keratinocytes are the executors of immune cell functions during the onset of psoriasis, and the IL-23 / IL-17 axis is key to driving psoriasis. Activation of plasmacytoid dendritic cells promotes the maturation of myeloid dendritic cells and the production of TNF-α, IL-12, and IL-23, leading to the activation of Th1 and Th17 and the subsequent secretion of inflammatory cytokines, such as TNF-α, IL-17, IL-21, and IL-22. Keratinocytes are then activated by these cytokines and produce antimicrobial peptides, cytokines, and chemokines, thereby promoting inflammatory responses. Keratinocytes play a crucial role in both the initiation and maintenance of psoriasis. Therefore, it is considered to start research on the treatment of psoriasis from the perspective of regulating keratinocytes.
[0004] Glucose metabolism is considered to be a key metabolic mechanism in psoriasis. Glucose uptake is carried out by glucose transporters, and studies have found that glucose transporter 1 (Glut 1) is significantly increased in the epidermis of patients and imiquimod (IMQ)-induced psoriasis mouse models. Keratinocyte-specific deletion of Glut 1 does not affect normal skin development and homeostasis, but improves psoriatic hyperplasia induced by IMQ and IL-1β. In addition, topical application of Glut 1 inhibitors can reduce skin hyperplasia and inflammation in psoriasis mouse models, so inhibiting glucose metabolism in keratinocytes can reduce psoriasis inflammatory responses. The IL-23 / IL-17 axis is an important link in the pathogenesis of psoriasis, and their production is regulated by other cytokines, one of which is thymic stromallymphopoietin (TSLP). TSLP is a cytokine expressed by epithelial cells (including keratinocytes) and plays an important role in skin inflammation. Studies have shown that TSLP is overexpressed in psoriasis patients, and TSLP secreted by mutant keratinocytes enhances the proliferation of non-mutant keratinocytes and the expression of VEGFα, while inhibition of TSLP can reduce this effect. Therefore, the regulation of keratinocyte proliferation by TSLP in the development of psoriasis inflammation is an important hallmark of psoriasis. In the process of sustained immune response, it is also crucial to directly activate suppressive Tregs to regulate inflammation and prevent the development of systemic inflammation.
[0005] Mesenchymal stem cells (MSCs) can secrete nutritional factors responsible for tissue regeneration and repair of tissue damage, and have a good effect in the treatment of skin diseases. However, studies have shown that direct use of MSC transplantation for treatment has major drawbacks, showing that the cell implantation rate and survival rate after transplantation are low, resulting in poor treatment effects for psoriasis and obvious inflammatory reactions. Summary of the invention
[0006] The present invention aims to solve the problems of poor therapeutic effect and obvious inflammatory response in the existing method of directly using MSC transplantation to treat psoriasis, and provides a preparation method and application of a psoriasis repair factor preparation.
[0007] The preparation method of the psoriasis repair factor preparation of the present invention comprises the following steps:
[0008] 1. Culture of Mesenchymal Stem Cells
[0009] Wharton's jelly was separated from umbilical cord tissue, and UMSCs were obtained by the slide method;
[0010] P1 UMCs were purified and then cultured in complete medium at 37°C and 5% CO 2The cells were cultured in an incubator, and when the cells adhered to 60%-80%, the cells were treated with intense pulsed light;
[0011] 2. Isolation and Extraction of Exosomes
[0012] UMSCs were cultured to the third generation. When the cells adhered to the wall to 50%-60%, they were switched to exosome-free culture medium and continued to be cultured. When the cells adhered to the wall to 90%-100%, the cell culture supernatant was collected and exosomes were extracted.
[0013] 3. Preparation of Preparations
[0014] The exosomes extracted in step 2 are diluted with physiological saline to prepare a preparation with a volume concentration of 20%-50%, which is the psoriasis repair factor preparation.
[0015] Furthermore, the wavelength of the intense pulsed light treatment in step 1 is 600-1200nm, the number of pulses is three pulses, the pulse width is 1-15ms, the pulse delay is 5-50ms, and the energy density is 15-35mJ / cm 2 .
[0016] Furthermore, the complete culture medium formula in step 1 is: MEM basal culture medium + 5% Helios serum substitute + 2 IU / mL heparin sodium + 1% penicillin-streptomycin.
[0017] Furthermore, the exosome-free medium in step 2 is obtained by ultracentrifuging the complete culture medium at 100,000×g for 16 h at 4° C., and collecting 2 / 3 of the volume of the upper layer of the culture medium, which is the exosome-free medium.
[0018] Furthermore, in step 2, ultracentrifugation is used to extract exosomes.
[0019] Furthermore, the specific steps of extracting exosomes by ultracentrifugation are as follows:
[0020] 1. Centrifuge the collected cell culture supernatant to remove live cells;
[0021] 2. Centrifuge at 2,000 × g at 4°C to remove dead cells;
[0022] 3. Centrifuge at 10,000 × g at 4°C to remove cell debris;
[0023] 4. Then transfer the supernatant to an ultrafiltration tube and collect the concentrate by centrifugation;
[0024] 5. Disinfect the outer wall of the ultrafiltration tube of the collected concentrate, move it to the clean bench, filter and transfer it to the ultracentrifuge tube;
[0025] 6. Ultracentrifuge at 100,000 × g for 75 min at 4°C and retain the precipitate at the bottom of the tube;
[0026] 7. Add PBS to resuspend, centrifuge at 4°C, 100,000 × g for 75 min, and retain the precipitate at the bottom of the tube;
[0027] 8. Resuspend the precipitate with pre-cooled PBS to obtain exosomes, and store at -80℃ for future use.
[0028] The present invention provides application of a psoriasis repair factor preparation in preparing a medicament for treating psoriasis.
[0029] The present invention provides application of a psoriasis repair factor preparation in inhibiting Glut 1 expression of keratinocytes.
[0030] The present invention provides application of a psoriasis repair factor preparation in inhibiting keratinocytes from secreting TSLP.
[0031] The present invention provides application of a psoriasis repair factor preparation in promoting proliferation and differentiation of Treg cells.
[0032] Beneficial effects of the present invention:
[0033] 1. In the process of MSCs culture, the present invention performs intense pulsed light treatment on MSCs to promote the secretion of MSCs exosomes and increase the content of psoriasis repair factors in exosomes, wherein the psoriasis repair factors are insulin-like growth factor-1 (IGF-1), interleukin 10 (IL-10) and inhibitor of cytokine signaling 3 (SOCS-3), etc. It has a good regulatory effect on the pathological keratinocytes in the development of psoriasis, and activates the immune self-healing ability of the skin through immune and metabolic pathways, thereby improving psoriasis.
[0034] 2. The present invention extracts exosomes secreted by MSCs after intense pulsed light treatment, which can inhibit the expression of Glut 1 that increases sharply during the development of psoriasis, and inhibit the excessive proliferation of keratinocytes and the development of inflammation by regulating glucose metabolism, thereby reducing the occurrence and development of psoriasis hyperplasia and inflammation.
[0035] 3. The exosomes extracted by the present invention can inhibit the secretion of TSLP by keratinocytes during the development of psoriasis, thereby reducing cell proliferation and alleviating skin inflammation, thereby achieving the effect of improving psoriasis.
[0036] 4. The present invention extracts exosomes secreted by MSCs after intense pulsed light treatment, which can promote the proliferation and differentiation of Treg cells in the development of psoriasis inflammation, restore the immunosuppressive characteristics of functionally impaired Treg cells, regulate the body's immune homeostasis, awaken the skin's immune function, and play a role in alleviating psoriasis inflammation.
[0037] 5. The psoriasis repair factor preparation of the present invention is prepared from exosomes secreted by MSCs after intense pulsed light treatment. The special conditions of intense pulsed light are used to cause specific changes in MSCs, resulting in exosomes rich in skin self-healing factors that regulate psoriasis inflammation, which can reduce the development of psoriasis inflammation through immune regulation and glucose metabolism, thereby improving psoriasis symptoms and providing new ideas for the treatment of skin diseases such as psoriasis. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 The identification results of TSG101, a surface marker protein of MSCs and exosomes;
[0039] Figure 2 This is the identification result of the surface marker protein CD9 of MSCs and exosomes;
[0040] Figure 3 This is the identification result of CD63, the surface marker protein of MSCs and exosomes;
[0041] Figure 4 is the change of Glut 1 mRNA expression level in keratinocytes;
[0042] Figure 5 is the change of TSLP mRNA expression level in keratinocytes;
[0043] Figure 6 Comprehensive scoring of erythema, scaling, and thickening of the mouse back skin;
[0044] Figure 7 The changes in the mRNA expression level of inflammatory factor TNF-α in the skin lesions of mice;
[0045] Figure 8 The changes in the mRNA expression level of the inflammatory factor IFN-γ in the skin lesions of mice;
[0046] Fig. 9 The changes in the mRNA expression level of the inflammatory factor IL-1β in the skin lesions of mice;
[0047] Fig.10 The changes in the mRNA expression level of inflammatory factor IL-17A in the skin lesions of mice;
[0048] Fig.11 The changes in the mRNA expression level of inflammatory factor IL-23 in the skin lesions of mice;
[0049] Fig.12 The changes in the mRNA expression level of inflammatory factor IL-27 in the skin lesions of mice;
[0050] Fig.13The expression of Foxp 3 mRNA in the skin lesions of mice;
[0051] Fig.14 The weight changes of mouse spleen. DETAILED DESCRIPTION
[0052] The embodiments of the present invention are described in detail below. The following embodiments are implemented on the premise of the technical solution of the present invention, and detailed implementation schemes and specific operation processes are given, but the protection scope of the present invention is not limited to the following embodiments.
[0053] Embodiment 1:
[0054] The preparation method of the psoriasis repair factor preparation of this embodiment comprises the following steps:
[0055] 1. Cultivation of stem cells
[0056] Wharton's jelly was separated from umbilical cord tissue and UMSCs were obtained by the slide method.
[0057] P1 UMCs were purified and then cultured in complete medium at 37°C and 5% CO 2 The cells were cultured in an incubator, and when the cells adhered to 80%, the cells were treated with intense pulsed light, wherein the wavelength of the intense pulsed light treatment was 1000 nm, the number of pulses was three, the pulse width was 10 ms, the pulse delay was 20 ms, and the energy density was 35 mJ / cm 2 ;
[0058] The complete culture medium formula is: MEM basal culture medium + 5% Helios serum substitute + 2IU / mL heparin sodium + 1% penicillin streptomycin;
[0059] 2. Isolation and Extraction of Exosomes
[0060] UMSCs were cultured to the third generation. When the cells adhered to 60%, they were switched to exosome-free medium and continued to be cultured. When the cells adhered to 90%, the cell culture supernatant was collected into a 50 mL centrifuge tube to extract exosomes (S-Exo).
[0061] The exosome-free medium is prepared by ultracentrifuging the complete culture medium at 4° C. and 100,000×g for 16 h, and collecting 2 / 3 of the volume of the upper layer of the culture medium, which is the exosome-free medium.
[0062] Exosomes were extracted by ultracentrifugation. The specific method is as follows:
[0063] (1) The collected supernatant was centrifuged at 300 × g for 10 min at 4°C to remove live cells;
[0064] (2) centrifugation at 2,000 × g for 10 min at 4°C to remove dead cells;
[0065] (3) centrifugation at 10,000 × g for 30 min at 4°C to remove cell debris;
[0066] (4) Transfer the supernatant to a 100KD 50mL ultrafiltration tube and collect the concentrate by centrifugation;
[0067] (5) Disinfect the outer wall of the ultrafiltration tube of the collected concentrate, move it to an ultraclean bench, and filter and transfer it to an ultracentrifuge tube;
[0068] (6) Ultracentrifuge at 100,000 × g for 75 min at 4°C and retain the pellet at the bottom of the tube;
[0069] (7) Add PBS to resuspend, centrifuge at 100,000 × g for 75 min at 4°C, and retain the precipitate at the bottom of the tube;
[0070] (8) Resuspend the precipitate in 150 μL pre-cooled PBS to obtain exosomes, which are stored at -80°C for future use.
[0071] 3. The exosomes (S-Exo) extracted in step 2 are diluted with physiological saline to prepare an S-Exo preparation with a volume concentration of 30%, which is a psoriasis repair factor preparation.
[0072] Embodiment 2:
[0073] The UMSCs of this embodiment have not been subjected to strong pulse treatment.
[0074] 1. Cultivation of stem cells
[0075] Wharton's jelly was separated from umbilical cord tissue and UMSCs were obtained by the slide method.
[0076] P1 UMCs were purified and then cultured in complete medium at 37°C and 5% CO 2 Culture in an incubator;
[0077] The complete culture medium formula is: MEM basal culture medium + 5% Helios serum substitute + 2IU / mL heparin sodium + 1% penicillin streptomycin;
[0078] 2. Isolation and Extraction of Exosomes
[0079] UMSCs were cultured to the third generation. When the cells adhered to 60%, they were switched to exosome-free medium and cultured. When the cells adhered to 90%, the cell culture supernatant was collected into a 50 mL centrifuge tube and exosomes (N-Exo) were extracted. The method for extracting exosomes was the same as that in Example 1.
[0080] The exosome-free medium is prepared by ultracentrifuging the complete culture medium at 4° C. and 100,000×g for 16 h, and collecting 2 / 3 of the volume of the upper layer of the culture medium, which is the exosome-free medium.
[0081] 3. Dilute the exosomes (N-Exo) extracted in step 2 with normal saline to prepare an N-Exo preparation with a volume concentration of 30%.
[0082] Example 3: Identification of exosome surface markers and psoriasis repair-related cytokines
[0083] For the exosomes in Example 1 (S-Exo) and the exosomes in Example 2 (N-Exo), Western Blot was used to detect exosome marker proteins, and ELISA was used to detect the content of psoriasis repair-related cytokines.
[0084] (1) MSCs and exosome protein samples were mixed with 5× buffer at a ratio of 4:1 and incubated in a 90°C water bath for 8-10 min;
[0085] (2) Prepare gel according to the instructions of the SDS-PAGE gel preparation kit;
[0086] (3) After the gel solidifies, add the protein marker and exosome protein sample to the spotting well;
[0087] (4) Install the electrophoresis tank, observe whether the concentrated gel leaks at 70V, adjust to 120V after 30 minutes, and end the electrophoresis after about 60-90 minutes;
[0088] (5) Remove the gel after cutting off the concentrated gel and useless areas;
[0089] (6) Prepare a PVDF membrane of the same size as the separation gel and activate it with methanol for 1 min;
[0090] (7) Install the transfer device in order, from negative electrode to positive electrode, fiber mat, three-layer filter paper, gel, PVDF membrane, three-layer filter paper, fiber mat, place the transfer device in the transfer tank, and operate at 400 mA for 30 min;
[0091] (8) Remove the PVDF membrane and block it with 5% skim milk at 25°C for 2 h, then rinse it twice with TBST for 5 min each time;
[0092] (9) Incubate with TSG101, CD9, and CD63 antibodies at 4°C overnight (about 10 h), and rinse thoroughly with TBST five times every other day, 10 min each time;
[0093] (10) Incubate with the corresponding secondary antibody at room temperature for 1 h, and rinse with TBST 5 times, 10 min each time;
[0094] (11) The PVDF membrane was covered with 1:1 ECL luminescent developer and the experimental results were observed using a gel imaging system.
[0095] The results of surface marker identification of MSCs and exosomes are as follows Figure 1-Figure 3 As shown, in the exosome samples, the surface marker proteins TSG101, CD9 and CD63 were all positive, but were basically not expressed in MSCs, proving that the exosomes were successfully extracted. Compared with the normally cultured MSCs, in the exosomes secreted by MSCs treated with intense pulsed light in Example 1, the expression levels of the three exosome surface marker proteins TSG101, CD9 and CD63 were significantly increased, indicating that intense pulsed light irradiation can promote the secretion of exosomes from MSCs.
[0096] According to the instructions of IGF-1, IL-10 and SOCS-3 ELISA kits, the changes in the content of psoriasis repair-related cytokines in MSCs exosomes after pulse treatment were detected. The results are shown in Table 1. The contents of IGF-1, IL-10 and SOCS-3 in MSCs exosomes after pulse treatment were significantly higher than those in conventional cultured cell exosomes, indicating that intense pulsed light irradiation can increase the content of psoriasis repair-related cytokines in MSCs exosomes.
[0097] Table 1 Changes in the content of psoriasis repair-related cytokines in MSCs exosomes after intense pulsed light treatment
[0098]
[0099] Example 4: Effects of MSC-Exo treated with intense pulsed light on inflammatory cells
[0100] Studies have found that the expression levels of IL-1β mRNA and protein in psoriatic lesions are significantly increased, and are mainly secreted by human macrophages, dendritic cells and keratinocytes. IL-1β can stimulate keratinocytes to secrete chemokines, attract T cells that can produce IL-17, and then induce the occurrence and development of skin inflammation (such as psoriasis).
[0101] Therefore, this example uses IL-1β to stimulate keratinocytes to simulate the inflammatory response of psoriasis and verify the in vitro effect of exosomes S-Exo. The specific steps are as follows.
[0102] Mouse keratinocytes were cultured at 37°C and 5% CO 2The keratinocytes were cultured in an incubator. The keratinocytes were divided into four groups: control group, IL-1β (25 ng / mL) treatment group, exosome N-Exo (50 ng / μL) and IL-1β simultaneous treatment group, and exosome S-Exo (50 ng / μL) and IL-1β simultaneous treatment group. The keratinocytes in the control group were treated with PBS; the IL-1β treatment group was treated with 25ng / mL IL-1β for 24h when the keratinocytes adhered to 70%-80%; the exosome N-Exo and IL-1β treatment group was treated with 25ng / mL IL-1β for 24h when the keratinocytes adhered to 70%-80%, and then treated with 50ng / μL N-Exo for 12h; the exosome S-Exo and IL-1β treatment group was treated with 25ng / mL IL-1β for 24h when the keratinocytes adhered to 70%-80%, and then treated with 50ng / μL S-Exo for 12h. The cells were collected for q-PCR (Glut 1 and TSLP) detection.
[0103] Glucose is the main energy source for all cells, and glucose uptake is achieved through the activity of glucose transporters, especially the glucose transporter (GLUT) family. Glucose transporter-1 (Glut 1) is the most widely expressed glucose transporter and plays an important role in cellular energy metabolism. Glut 1 is weakly expressed in healthy skin, but strongly expressed in the lesions of psoriasis patients. Glucose metabolism is related to cell proliferation and differentiation and is essential for cell activity. In the pathogenesis of psoriasis, upregulation of glucose metabolism is considered to be an important factor in promoting hyperplasia, inflammation, and angiogenesis. Glut 1 expression is abnormal in psoriasis patients. Glucose metabolism can be regulated by inhibiting Glut 1 expression, so that overproliferated cells return to normal, thereby inhibiting hyperplasia and inflammation.
[0104] The results of changes in the mRNA expression levels of Glut 1 and TSLP in keratinocytes are as follows Figure 4 and Figure 5 As shown in the figure, Glut1 is responsible for regulating glucose metabolism, and TSLP can regulate cell proliferation in the development of psoriasis. After inflammatory cells were treated with exosomes, the expression of Glut1 and TSLP was significantly downregulated, among which the IL-1β+S-Exo group was the most significant, proving that the exosomes S-Exo secreted by MSCs treated with intense pulsed light can regulate the glucose metabolism and cell proliferation of keratinocytes, thereby alleviating the inflammatory response of psoriasis.
[0105] Example 5: Therapeutic effect on psoriasis model mice
[0106] 60 mg of imiquimod (IMQ) was topically applied on the back skin of male mice after shaving for 6 consecutive days to establish a local psoriasis model in mice. The model mice were divided into four groups: the first group was a healthy control group (Control); the second group was a model control group (IMQ, i.e., a saline sham treatment group); the third group was a conventional exosome preparation treatment group (N-Exo) of Example 2; and the fourth group was a psoriasis repair factor preparation treatment group (PRAF preparation) of Example 1. The animals in the healthy control group did not receive any treatment, and the other three groups of animals began treatment on the second day of IMQ modeling. The injection dose and time of the three groups of animals were unified, and the mice were injected into the tail vein (10-30 μL / g) and multiple injections were made locally at the lesion site (5-20 μL / cm 2 ), once a day for 7 days, and the comprehensive scores of erythema, scaling and thickening of the back skin of mice were used to indicate the severity of dermatitis on the back of the skin on the 1st, 3rd, 5th and 7th days (each score represents: 0 for no increase, 1 for slight increase, 2 for moderate increase, and 3 for significant increase). The mice were killed the next day after the completion of the treatment, and blood, skin from the lesion site and spleen were collected. The blood was centrifuged to collect serum for serum ELISA detection; the skin tissue was ground for q-PCR detection (TNF-α, IFN-γ, IL-1β, IL-17A, IL-23 and IL-27mRNA); the spleen weight was weighed using an electronic balance to compare the changes in splenomegaly before and after treatment.
[0107] Table 2 Mouse serum ELISA test results (pg / mL)
[0108]
[0109] Experimental results: Figure 6 The results are a comprehensive score for the degree of erythema, scaling and thickening of the mouse back skin, showing that N-Exo and PRAF preparations can reduce the severity of psoriasis, among which the PRAF preparation group in Example 1 has a more significant effect.
[0110] Table 2 shows the expression of inflammatory factors in serum, showing that the expression of inflammatory factors in the skin of the lesions of psoriasis model mice was significantly increased, and the expression of inflammatory factors TNF-α, IFN-γ, IL-1β, IL-17A, IL-23 and IL-27 was significantly decreased after treatment with N-Exo and PRAF preparations, and the PRAF preparation treatment group of Example 1 had a better effect.
[0111] Figure 7-Figure 12The mRNA expression of inflammatory factors in the skin of mouse lesions showed that after treatment with N-Exo and PRAF preparations, the expression of inflammatory factors TNF-α, IFN-γ, IL-1β, IL-17A, IL-23 and IL-27 was significantly decreased, among which the therapeutic effect of PRAF preparation in Example 1 was more significant.
[0112] Fig.13 The changes in Treg cells in the mouse skin lesions (Foxp 3 mRNA expression) are shown. The transcription factor Foxp3 plays an important role in regulating the development and function of Treg cells, so the mRNA expression level of Foxp 3 is detected to indicate the changes in Treg. The results showed that the expression of Foxp 3 in the psoriasis model group was significantly lower than that in the healthy control group, while the expression of Foxp 3 was significantly upregulated after treatment with N-Exo and PRAF preparations, among which the upregulation in the PRAF preparation treatment group of Example 1 was the most significant.
[0113] Fig.14 The figure shows the changes in spleen weight of mice. The psoriasis model mice had splenomegaly. After treatment with N-Exo and PRAF preparations, the spleen weight decreased significantly. Among them, the therapeutic effect of PRAF preparation in Example 1 was more significant.
[0114] The above results indicate that the exosome preparations rich in specific PRAF secreted by MSCs treated with intense pulsed light can inhibit the production of inflammatory factors, regulate immune function, activate skin self-healing ability, and thus reduce the inflammatory response of psoriasis.
Claims
1. A method for preparing a psoriasis repair factor preparation, characterized in that: The method comprises the following steps:
1. Culture of Mesenchymal Stem Cells Wharton's jelly was separated from umbilical cord tissue, and UMSCs were obtained by the slide method; P1 generation UMSCs were purified and then cultured with complete medium in a 37°C, 5% CO2 incubator. When the cells adhered to 60%-80%, the cells were treated with intense pulsed light; 2. Isolation and Extraction of Exosomes UMSCs were cultured to the third generation. When the cells adhered to the wall to 50%-60%, they were switched to exosome-free culture medium and continued to be cultured. When the cells adhered to the wall to 90%-100%, the cell culture supernatant was collected and exosomes were extracted.
3. Preparation of Preparations The exosomes extracted in step 2 are diluted with physiological saline to prepare a preparation with a volume concentration of 20%-50%, which is the psoriasis repair factor preparation.
2. The method for preparing a psoriasis repair factor preparation according to claim 1, characterized in that: The wavelength of the intense pulsed light treatment in step 1 is 600-1200nm, the number of pulses is three pulses, the pulse width is 1-15ms, the pulse delay is 5-50ms, and the energy density is 15-35mJ / cm 2 .
3. A method for preparing a psoriasis repair factor preparation according to claim 1 or 2, characterized in that: The complete culture medium formula in step 1 is: MEM basal culture medium + 5% Helios serum substitute + 2 IU / mL heparin sodium + 1% penicillin-streptomycin.
4. The method for preparing a psoriasis repair factor preparation according to claim 1, characterized in that: The exosome-free medium in step 2 is obtained by ultracentrifuging the complete culture medium at 100,000×g for 16 h at 4° C., and collecting 2 / 3 of the volume of the upper layer, which is the exosome-free medium.
5. The method for preparing a psoriasis repair factor preparation according to claim 1, characterized in that: In step 2, exosomes were extracted by ultracentrifugation.
6. The method for preparing a psoriasis repair factor preparation according to claim 5, characterized in that: The specific steps of extracting exosomes by ultracentrifugation are as follows: 1) Centrifuging the collected cell culture supernatant to remove live cells; 2) Centrifuge at 2,000 × g at 4°C to remove dead cells; 3) centrifugation at 10,000 × g at 4°C to remove cell debris; 4) The supernatant is then transferred to an ultrafiltration tube and the concentrate is collected by centrifugation; 5) Disinfect the outer wall of the ultrafiltration tube of the collected concentrate, move it to an ultraclean bench, and filter and transfer it to an ultracentrifuge tube; 6) Ultracentrifuge at 100,000 × g for 75 min at 4°C and retain the pellet at the bottom of the tube; 7) Add PBS to resuspend, centrifuge at 4°C, 100,000 × g for 75 min, and retain the precipitate at the bottom of the tube; 8) Resuspend the precipitate in pre-cooled PBS to obtain exosomes, and store at -80°C for future use.
7. Use of the psoriasis repair factor preparation prepared by the method as claimed in claim 1 in the preparation of drugs for treating psoriasis.
8. Use of the psoriasis repair factor preparation prepared by the method according to claim 1 in inhibiting the expression of Glut 1 in keratinocytes.
9. Use of the psoriasis repair factor preparation prepared by the method according to claim 1 in inhibiting keratinocytes from secreting TSLP.
10. Use of the psoriasis repair factor preparation prepared by the method according to claim 1 in promoting the proliferation and differentiation of Treg cells.
